가금류용 백신 시장 : 백신 유형, 대상 종, 투여 경로, 최종사용자, 유통 채널별 - 세계 예측(2026-2032년)

The Poultry Vaccine Market is projected to grow by USD 4.37 billion at a CAGR of 6.26% by 2032.

Poultry Vaccine Market Introduction

The poultry vaccine market is a critical pillar of global animal health, food security, and antimicrobial stewardship. Vaccines for broilers, layers, and breeders help prevent high-impact diseases such as Newcastle disease, infectious bronchitis, infectious bursal disease, Marek's disease, avian influenza, fowl pox, coccidiosis, and salmonellosis. These diseases can reduce flock productivity, increase mortality, disrupt trade, and raise the need for therapeutic interventions.

Demand is being reinforced by expanding poultry meat and egg consumption, stricter biosecurity expectations, and the economic importance of uninterrupted poultry supply chains. Verified guidance from organizations such as WOAH, FAO, WHO, USDA, and national veterinary authorities confirms that vaccination, when integrated with surveillance and farm-level biosecurity, remains one of the most effective tools for controlling endemic and transboundary poultry diseases.

Transformative Shifts in the Poultry Vaccine Landscape

The landscape is shifting from reactive disease treatment toward preventive flock health management. Producers are prioritizing vaccination schedules that protect day-old chicks, reduce production losses, and support consistent feed conversion performance. Hatchery-based vaccination, in-ovo delivery, and mass administration methods are gaining relevance because they improve coverage and reduce labor intensity across large commercial operations.

Another major shift is the rise of advanced vaccine platforms, including recombinant, vector-based, immune-complex, subunit, and live-attenuated products. These technologies are improving protection against evolving pathogens and enabling more targeted disease control. At the same time, regulators and buyers are placing greater emphasis on residue reduction, antimicrobial use reduction, traceability, documented flock health outcomes, and alignment with One Health principles.

Cumulative Impact of Artificial Intelligence on Poultry Vaccines

Artificial intelligence is beginning to influence poultry vaccine development, disease surveillance, and field execution. AI-enabled epidemiological modeling can help identify disease spread patterns, evaluate outbreak risk, and support decisions on vaccination timing. In research and development, machine learning can accelerate antigen screening, immune-response modeling, and strain selection for diseases with high mutation pressure.

AI also improves farm-level vaccine performance monitoring. Computer vision, environmental sensors, production analytics, and mortality pattern analysis can help detect early health deviations after vaccination or disease exposure. However, AI does not replace regulatory validation, challenge studies, cold-chain controls, or veterinary oversight. Its greatest value lies in making vaccination programs more predictive, measurable, and responsive.

Key Regional Insights Across Poultry Vaccine Adoption

Asia-Pacific remains central to poultry vaccine demand due to large poultry populations, intensive production systems, and recurring pressure from Newcastle disease, infectious bronchitis, infectious bursal disease, and avian influenza. China and India continue to shape regional volume, while Southeast Asian countries are strengthening biosecurity and vaccination infrastructure through commercial integration and national disease-control programs. North America is characterized by science-based veterinary oversight, strong hatchery vaccination adoption, and heightened avian influenza preparedness following recent highly pathogenic avian influenza events documented by USDA and CFIA.

Latin America, led by Brazil and Mexico, benefits from export-oriented poultry production and structured disease-control programs that prioritize flock health, traceability, and continuity of trade. Europe is driven by strict animal health regulation, advanced surveillance, and EU-level disease notification systems, with vaccination strategies shaped by risk-based control, welfare expectations, and antimicrobial reduction goals. The Middle East depends on vaccine-supported poultry self-sufficiency initiatives, particularly where climate stress, water constraints, and import dependence create supply risk. Africa shows strong long-term need as vaccination against Newcastle disease remains essential for both commercial farms and backyard poultry systems, where poultry contributes to nutrition, household income, and rural resilience.

Key Group Insights for Poultry Vaccine Strategy

ASEAN markets are expanding poultry vaccination programs as commercial integrators modernize hatcheries and governments strengthen avian disease surveillance, particularly for Newcastle disease and avian influenza. The GCC is focused on food security, domestic poultry capacity, and vaccine-supported biosecurity in high-temperature production environments where flock stress can increase disease-management complexity. The European Union emphasizes harmonized veterinary regulation, pharmacovigilance, residue control, and disease reporting, making compliance, documentation, and post-authorization monitoring essential for suppliers.

BRICS countries represent a large share of global poultry production and are influential in volume demand, local manufacturing capability, and disease-control policy, with China, India, Brazil, Russia, and South Africa each facing distinct poultry health priorities. G7 markets are distinguished by advanced veterinary infrastructure, innovation funding, diagnostic capacity, and strong regulatory scrutiny. NATO countries overlap with several advanced animal health markets where resilience of food supply chains, outbreak readiness, and cross-border disease intelligence increasingly inform poultry vaccine procurement and biosecurity planning.

Key Country Insights in Poultry Vaccine Demand

The United States has one of the most developed poultry health ecosystems, supported by USDA disease surveillance, strong integrator networks, and widespread hatchery vaccination. Canada emphasizes coordinated animal health management and avian influenza preparedness, while Mexico combines large domestic poultry consumption with sustained demand for Newcastle disease, infectious bronchitis, infectious bursal disease, and coccidiosis control. Brazil's export-focused poultry industry relies on robust vaccination and disease-prevention systems to protect international market access and support compliance with importing-country requirements.

In Europe, the United Kingdom, Germany, France, Italy, and Spain apply strict veterinary controls, with demand shaped by biosecurity, antimicrobial reduction, traceability, and poultry welfare expectations. Russia has a large domestic poultry base with continued emphasis on disease self-sufficiency, local supply reliability, and vaccination against endemic poultry pathogens. In Asia-Pacific, China and India anchor high-volume demand through large broiler and layer populations, Japan and South Korea prioritize advanced biosecurity, monitoring, and high-standard veterinary oversight, and Australia maintains strict animal health controls supported by quarantine, surveillance, and monitoring systems.

Actionable Recommendations for Poultry Vaccine Leaders

Industry leaders should align vaccine portfolios with disease prevalence, production type, and regulatory requirements in each market. Companies that combine core vaccines for Newcastle disease, infectious bronchitis, Marek's disease, infectious bursal disease, coccidiosis, and salmonella with advanced recombinant or vector-based solutions will be better positioned to meet integrator needs.

Strategic priorities include strengthening cold-chain reliability, expanding hatchery-service capabilities, investing in AI-supported surveillance tools, and generating field evidence that demonstrates flock-level performance. Partnerships with veterinary authorities, universities, diagnostics providers, and poultry integrators can improve disease intelligence and accelerate product adoption. Leaders should also prepare for stricter documentation, pharmacovigilance, traceability, and sustainability expectations across export-oriented markets.

Research Methodology for Poultry Vaccine Insights

This executive summary is developed through secondary research and expert synthesis using verified public-domain sources, including WOAH disease information, FAO poultry health guidance, WHO antimicrobial resistance principles, USDA and CFIA avian influenza updates, European regulatory frameworks, and national veterinary authority publications. Market interpretation is grounded in disease burden, poultry production trends, regulatory signals, adoption patterns, and established veterinary immunization practices.

The methodology emphasizes triangulation across scientific literature, government disease surveillance, regulatory guidance, and industry practice. Insights are reviewed for relevance to commercial poultry vaccination, including broilers, layers, breeders, hatchery operations, and integrated production systems. No unsupported market-size, market-share, or forecasting claims are used; emphasis is placed on verifiable demand drivers and strategic implications.

Conclusion: Poultry Vaccines as a Food Security Imperative

Poultry vaccines will remain indispensable to animal health, protein security, and sustainable poultry production. As disease pressure intensifies and global trade becomes more sensitive to outbreaks, producers need vaccination programs that are scientifically validated, operationally practical, and supported by diagnostics, surveillance, and biosecurity.

The market's next phase will be shaped by advanced vaccine platforms, stronger regional preparedness, AI-enabled decision support, and rising expectations for antimicrobial stewardship. Suppliers that deliver reliable products, field evidence, regulatory compliance, and integrated technical support will be best positioned to address long-term needs in the global poultry vaccine market.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Poultry Vaccine Market, by Vaccine Type

• 7.1. Live Attenuated Vaccines
  • 7.1.1. Lentogenic
  • 7.1.2. Mesogenic
  • 7.1.3. Thermostable
• 7.2. Inactivated Vaccines
• 7.3. Conjugate Vaccines
• 7.4. Recombinant Vaccines
  • 7.4.1. Vector-based Vaccines
  • 7.4.2. Subunit Vaccines
  • 7.4.3. DNA Vaccines
• 7.5. Toxoid Vaccines

8. Poultry Vaccine Market, by Species

• 8.1. Chicken
• 8.2. Duck
• 8.3. Turkey

9. Poultry Vaccine Market, by Route Of Administration

• 9.1. Injectable
  • 9.1.1. Intramuscular
  • 9.1.2. Subcutaneous
• 9.2. Oral
• 9.3. Spray
  • 9.3.1. Aerosol
  • 9.3.2. Fogging

10. Poultry Vaccine Market, by End User

• 10.1. Backyard Farms
• 10.2. Commercial Farms
  • 10.2.1. Broiler Farms
  • 10.2.2. Layer Farms
• 10.3. Research Institutes

11. Poultry Vaccine Market, by Distribution Channel

• 11.1. Online Channels
  • 11.1.1. E Commerce Marketplaces
  • 11.1.2. Manufacturer Websites
• 11.2. Veterinary Hospitals
  • 11.2.1. Government Hospitals
  • 11.2.2. Private Hospitals
• 11.3. Veterinary Pharmacies
  • 11.3.1. Chain Pharmacies
  • 11.3.2. Independent Pharmacies

12. Poultry Vaccine Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Poultry Vaccine Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Poultry Vaccine Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Biogenesis Bago S.A.
• 16.2. Bioproperties Pty Ltd
• 16.3. Biovet S.A.
• 16.4. Bioveta, a.s.
• 16.5. Boehringer Ingelheim International GmbH
• 16.6. Ceva Sante Animale S.A.
• 16.7. China Animal Husbandry Industry Co., Ltd.
• 16.8. CZ Veterinaria S.A.
• 16.9. Elanco Animal Health Incorporated
• 16.10. Hester Biosciences Limited
• 16.11. HIPRA S.A.
• 16.12. Huvepharma EAD
• 16.13. Indian Immunologicals Ltd.
• 16.14. Indovax Private Limited
• 16.15. Jinyu Bio-Technology Co., Ltd.
• 16.16. KM Biologics Co., Ltd.
• 16.17. Merck & Co., Inc.
• 16.18. Neogen Corporation
• 16.19. Phibro Animal Health Corporation
• 16.20. SAN Group Biotech Germany GmbH
• 16.21. Tianjin Ringpu Bio-Technology Co., Ltd.
• 16.22. Vaksindo Satwa Nusantara
• 16.23. Vaxxinova International B.V.
• 16.24. Venky's India Limited
• 16.25. Vetoquinol S.A.
• 16.26. Virbac S.A.
• 16.27. Zoetis Inc.
• 16.28. Zydus Animal Health Limited